Dramatic response to cholestyramine in a patient with Graves' disease resistant to conventional therapy

Thyroid

Volumn 18, Issue 10, 2008, Pages 1115-1117

  Sebastián Ochoa, Arántzazu ^a   Quesada Charneco, Miguel ^a   Fernández García, Diego ^b   Reyes García, Rebeca ^c   Rozas Moreno, Pedro ^a   Escobar Jiménez, Fernando ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL RAFAEL MÉNDEZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; COLESTYRAMINE; DEXAMETHASONE; IODINE; LEVOTHYROXINE; LIOTHYRONINE; LUGOL; PROPRANOLOL; RADIOACTIVE IODINE; THIAMAZOLE; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ADD ON THERAPY; ADULT; ARTICLE; CASE REPORT; DRUG DOSE INCREASE; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; PRIORITY JOURNAL; THYROID SCINTISCANNING; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTITHYROID AGENTS; CHOLESTYRAMINE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EHLERS-DANLOS SYNDROME; FEMALE; GRAVES DISEASE; HUMANS; IODINE; METHIMAZOLE; PROPRANOLOL; TREATMENT OUTCOME;

EID: 53649092828     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0094     Document Type: Article

References (14)

1. Nayak B, Hodak SP 2007 Hyperthyroidism. Endocrinol Metab Clin North Am 36:617-656.
2. Cooper DS 2005 Antithyroid drugs. N Engl J Med 352:905-917.
3. Northcutt RC, Stiel JN, Hollifield JW, Stant EG, Jr. 1969 The influence of cholestyramine on thyroxine absorption. JAMA 208:1857-1861.
4. Solomon BL, Wartofsky L, Burman KD 1993 Adjunctive cholestyramine therapy for thyrotoxicosis. Clin Endocrinol (Oxford) 38:39-43.
5. Mercado M, Mendoza-Zubieta V, Bautista-Osorio R, Espinoza de los Monteros AL 1996 Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. J Clin Endocrinol Metab 81:3191-3193.
6. Tsai WC, Pei D, Wang TF, Wu DA, Li JC, Wei CL, Lee CH, Chen SP, Kuo SW 2005 The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism. Clin Endocrinol (Oxford) 62:521-524.
7. Roffi M, Cattaneo F, Brandle M 2005 Thyrotoxicosis and the cardiovascular system. Minerva Endocrinol 30:47-58.
8. 4-14C and its degradation products in a hypercholesterolemic patient. J Clin Invest 47:1664-1671.
9. Fletcher GF, Fletcher BJ, Whitner JT, Staggers J, Almon L 1995 Effects of variable doses and formulations of cholestyramine on elevated serum low-density lipoprotein cholesterol. Am J Cardiol 75:738-739.
10. Singh N, Hershman JM 2003 Interference with the absorption of levothyroxine. Curr Opin Endocrinol Diabetes 10:347-352.
11. Witztum JL, Jacobs LS, Schonfeld G 1978 Thyroid hormone and thyrotropin levels in patient placed on colestipol. J Clin Endocrinol Metab 46:838-840.
12. Hagag P, Nissenbaum H, Weiss M 1998 Role of colestipol in the treatment of hyperthyroidism. J Endocrinol Invest 21:725-731.
13. Shakir KM, Michaels RD, Hays JH, Potter BB 1993 The use of bile acid sequestrants to lower serum thyroid hormones in iatrogenic hyperthyroidism. Ann Intern Med 118:112-113.
14. de Luis DA, Dueñas A, Martin J, Abad L, Cuella L, Aller R 2002 Light symptoms following a high-dose intentional L-thyroxine ingestion treated with cholestyramine. Horm Res 57:61-63.